AtriCure (ATRC) Jumps 75% In 90 Days, Is The Stock Now Too Expensive?

AtriCure (ATRC) has drawn fresh attention after recent share gains over the past 3 months, bringing its longer term track record and current valuation metrics back into focus for investors.

AtriCure’s recent rally has been sharp, with a 90 day share price return of 74.76% feeding into a year to date gain of 46.86% and a 1 year total shareholder return of 55.40%, which points to momentum building rather than fading around the US$57.67 level.

Scan beyond AtriCure’s surge and weigh it against a hand-picked group of resilient healthcare and medical device companies in the list of solid balance sheet and fundamentals (25 results).

The rally now forces a simple question: Does AtriCure’s surge toward US$57.67 mainly mirror improving business results, or is it mostly a reset in investor sentiment that the current valuation now needs to justify?

Most Popular Narrative: 49% Overvalued

AtriCure’s most followed valuation narrative pegs fair value at $38.60, which sits well below the recent $57.67 share price and frames the latest rally as rich against those assumptions.

The current valuation implies that AtriCure’s share price already reflects expectations for continued double digit revenue growth, expanding EBITDA margins toward management’s Vision 2030, and successful execution on large clinical programs that are still several years from fully paying off.

See why 0 investors see AtriCure as 49% overvalued.

Result: Fair Value of $38.60 (OVERVALUED)

Still, several things could flip this bearish AtriCure story, including faster BoxX-NoAF and LeAAPS progress or stronger-than-feared pain management adoption.

Find out about the key risks to this AtriCure narrative.

Next Steps

Sentiment around AtriCure is clearly split, with optimism balancing concern over valuation. Treat this as a prompt to review the numbers yourself and move quickly to shape your own stance with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond AtriCure?

If AtriCure has your attention, do not stop here. Expand your watchlist with fresh ideas that could better match your goals and risk tolerance.

• Spot potential bargains early and scan a curated pool of companies trading below their estimated worth with the 33 high quality undervalued stocks.
• Strengthen your income stream and focus on stocks that pair robust balance sheets with meaningful yields using the 7 dividend fortresses.
• Zero in on resilience and filter for businesses with lower risk profiles that still offer room for upside through the 31 resilient stocks with low risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com